United States Closed System Transfer Devices Market

United States Closed System Transfer Devices Market Summary

As per Transpire Insight Analysis the United States Closed System Transfer Devices Market size is estimated at USD 648.5 Million in 2025 and is anticipated to reach USD 1345.7 Million by 2033, growing at a CAGR of 9.58% from 2026 to 2033.

The United States Closed System Transfer Devices Market sort of helps healthcare facilities handle hazardous drugs more safely by keeping leakage down, reducing contamination, and limiting worker exposure when drugs are being prepared and then administered. You can see this especially in oncology pharmacies, hospitals, and outpatient treatment centers, where drug transfers happen over and over , so occupational safety risk builds up if controls are weak. Over the last 3–5 years, the market has kind of moved away from only basic containment devices, and it is now leaning into more integrated systems. These are often built around standardized drug-handling workflows, plus tighter safety controls. 

One noticeable structural change is that closed transfer technologies are being adopted more widely, not just in hospital pharmacies, but also in ambulatory care settings. Newer expectations for hazardous-drug handling , along with more strict workplace safety practices, pushed this shift forward. Then the COVID-19 pandemic came in , it disrupted pharmaceutical supply chains, and it really made the need for controlled and reliable medication-handling processes feel urgent. 

As facilities focus on less exposure, smoother workflow consistency, and compliance, procurement is moving toward systems that blend safety with operational efficiency. In other words, demand is supporting broader adoption and also recurring device revenues.

United States Closed System Transfer Devices Market Size & Forecast:

• United States Closed System Transfer Devices Market Size 2025: USD 648.5 Million
• Expected Market Value 2033: USD 1345.7 Million
• Forecast CAGR: 9.58%
• Key Profile: BD (Becton Dickinson), ICU Medical, Equashield LLC, Simplivia Healthcare, Yukon Medical, Baxter International, B. Braun Melsungen AG, Fresenius Kabi, Smiths Medical, CODAN Medizinische Geräte, West Pharmaceutical Services, Corvida Medical, JMS Co. Ltd., MedXL Inc., Cardinal Health.

Key Market Insights

• North America is basically running the broader market, with about 42.8% share in 2025. This is backed by pretty strict USP <800> enforcement and, U.S. uptake. Even so, the pace looks solid going forward.
• The U.S. is still the fastest-growing national market through 2031, where compliance driven procurement is helping push CSTD adoption. That shows up across oncology pharmacies and also hospitals, kind of in a steady trickle that keeps growing.
• In the technology mix, diaphragm-based devices led the U.S. segment in 2024, which points to proven vapor-containment capability during hazardous-drug handling. It’s not a small detail really, it seems to carry weight.
• Meanwhile, vial access components held a notable 46.12% global share in 2025. The driver is mostly high-volume chemotherapy preparation workflows, where throughput matters more than people think.
• For component growth, syringe safety devices are moving the quickest. They’re projected at 14.02% CAGR through 2031, as safer preparation workflows expand into more day-to-day use.
• When it comes to end users, hospitals and clinics dominate demand with 73.44% global share in 2025. This is largely because routine hazardous-drug compounding and administration keep needing closed transfer support, repeatedly, over time.
• Oncology centers are the fastest-growing end-user category too. They’re forecast to expand at a 14.05% CAGR through 2031, as exposure controls get stronger and get used more widely.
• On the product side, BD rolled out PhaSeal Optima as a next generation CSTD, highlighting self-sealing membranes, needle protection, vapor containment and improved ergonomics all together, without much compromise.
• EQUASHIELD then launched CellSHIELD in September 2025, and it’s expanding closed-system technology into cell and gene therapy manufacturing in a more targeted way.
• ICU Medical also advanced its IV portfolio in 2025, focusing on digital interoperability and safety capabilities around connected medication-delivery workflows. The idea is safer use with smoother integration.
• Competitively, Baxter, West Pharmaceutical Services, and B. Braun continue to matter as major contenders. They keep supporting strategic expansion across drug-transfer components and broader healthcare safety systems too.

What are the Key Drivers, Restraints, and Opportunities in the United States Closed System Transfer Devices Market?

USP <800> compliance is like the main thing pushing the United States Closed System Transfer Devices Market forward. The standard basically asks for controls across hazardous-drug storage, preparation, administration, and disposal, and it turns these worker-protection needs into actual procurement calls. Oncology treatment volume is another spark too , since chemo prep ends up creating the same exposure moments again and again. The more hazardous-drug workflows a facility has, the more “protected-transfer” steps it needs, so that ends up boosting steady device use and it also tends to make hospital replacements feel more like a routine cycle.

From a Transpire Insight review of regional procurement announcements and launch timing, supply-chain concentration is still the biggest execution risk. Implementation costs stay high and they behave like a structural wall because CSTDs are not just a swap… facilities also have to buy devices, change the workflow, train staff, and confirm compatibility. Market research points to high implementation costs and limited reimbursement as the key restraints. Together they slow the move away from conventional transfer equipment and they can delay procurement timelines, especially where hospitals need to defend incremental per-dose costs in a way that makes sense internally.

The next real opening sits in automation-linked closed-system compounding. EQUASHIELD already uses AI-based image processing plus predictive maintenance in production operations, and automated compounding systems then connect CSTD protection to pharmacy throughput. Cell and gene therapy is another expansion avenue too. EQUASHIELD’s 2025 CellSHIELD launch shows how closed-system tech can shift beyond the usual oncology setting into sterile bioprocessing.

What Has the Impact of Artificial Intelligence Been on the United States Closed System Transfer Devices Market?

AI is starting to bend closed-system drug-transfer routines a bit, but it’s mostly via automated compounding , image checking , production monitoring, and predictive maintenance—more than it is about letting systems directly control CSTD devices on their own. EQUASHIELD says it’s using AI models for image processing along the production line and for predictive maintenance, and the real time data helps spot calibration troubles tied to temperature and torque before the mechanical failures show up. Similar digital workflows can help with compliance tracking too, by stitching together device use, batch documentation, operator confirmations and exception occurrences inside pharmacy automation systems, so nothing feels “loose”. On top of that, machine learning models can sharpen demand forecasting by mixing oncology treatment timetables, past compounding volumes, inventory movements, and device consumption signals. Overall the outcome is usually fewer production pauses, better equipment utilization, and more disciplined inventory planning. Also, automated compounding that stays CSTD-compatible tends to lower the repetitive manual stuff and supports a steadier execution of the procedure. EQUASHIELD’s CellSHIELD expansion , to me, shows the wider trend toward controlled, closed loops in advanced manufacturing. One key catch still is the integration cost. The AI models need dependable production data, compatible equipment connections, validation, cybersecurity guardrails, and ongoing monitoring. And when failure-event history is sparse , prediction accuracy can get constrained, so human verification stays essential, especially for higher-risk pharmacy operations.

Key Market Trends

• Since 2023, USP <800> rollout has nudged hospitals toward more formal hazardous-drug risk appraisals and more disciplined engineering safeguards, across the whole prep and administration flow.
• In 2024 diaphragm-based devices kept the front-runner position as buyers leaned hard into verified vapor-containment results.
• During 2025, vial access devices captured 46.12% of the global component demand, and that really reinforces their place in high-volume chemotherapy preparation.
• By 2025, needleless systems will hit 63.55% global share, since many hospitals are prioritizing sharps reduction along with hazardous-drug containment, at the same time.
• In September 2025, EQUASHIELD rolled out CellSHIELD, and it basically extends closed-system know-how into cell and gene therapy manufacturing workflows.
• In 2025, AI use spread further inside CSTD manufacturing via image processing, plus predictive maintenance, with the goal of cutting down production downtime.
• Through 2031, syringe safety devices are forecast to rise at 14.02% CAGR, which points to greater emphasis on safer drug handling during preparation.
• Through 2031, oncology centers are expected to grow at 14.05% CAGR, because specialized treatment volumes keep increasing, along with the protected handling needs.
• In 2025, BD pushed PhaSeal Optima as a next-gen CSTD, featuring ergonomic design, self-sealing membranes, and strengthened hazardous-drug protection, too.
• By 2026, market competition is getting more and more tied to CSTD purchasing decisions that connect automation, workflow integration, training, and evidence-based safety validation.

United States Closed System Transfer Devices Market Segmentation

By Product Type : 

Vial access devices keep a major place because hospitals and pharmacies use vial based drug preparation in oncology, and also in hazardous-drug workflows, pretty much every day. Syringe safety devices are also getting strong take up, since healthcare facilities want safer transfer processes and less exposure risk while medication is being prepared. Bag and line access devices help keep prepared medicines moving in a controlled way during administration.

Then you have closed system transfer components, transfer sets, and injection adapters which kind of help things stay compatible across several medication handling stages. Needle free systems are getting more attention too, because hospitals are trying to reduce sharps related risks, yet still maintain controlled drug transfer. Membrane-to-membrane systems support containment during repeated connections, while accessories add a bit more flexibility to what teams already have.When it comes to product choice, it will keep depending on compatibility, how easy it feels to operate, safety performance and overall workflow efficiency.

By Technology : 

Membrane-to-membrane technology helps with controlled transfer, it basically keeps a closed pathway between connected parts so nothing “escapes” in between. Needleless technology has real commercial strength too, since care settings can lower needle-related injuries, and still keep their procedures safer and more steady. Closed connector technology also matters because it allows repeated connections across the whole drug preparation and administration routine.

Then there is air filtration, mechanical barrier, and pressure equalization, each one tackles a slightly different containment need during hazardous-drug work. Some operations go for hybrid systems, these mix more than one protective mechanism, and they can support the more complex pharmacy flow. Sealed transfer systems add another containment layer specifically when the drug is being moved. Adoption will really hinge on containment performance, fit with the equipment already in place, staff training needs, what validation demands, and of course procurement costs and approvals.

By Application : 

Hazardous drug handling still stays a central use case, because chemotherapy and other hazardous medicines kind of need controlled preparation and transfer, you know. Drug transfer in chemo keeps generating repeated device use across hospitals, oncology centers, and even specialty pharmacies. Pharmacy compounding also moves forward with steady adoption as more pharmacies roll out constrained procedures for medication preparation, not just general mixing.

Then drug administration makes it expand again, through protected transfer during medication delivery. Biopharmaceutical manufacturing looks like an emerging chance too, since advanced therapies need controlled processing environments and dependable contamination protection. Clinical research and lab use create smaller yet specialized demand, but it’s not nothing.And hospital pharmacy operations will remain important too, because centralized preparation depends on consistent handling procedures, equipment compatibility, and staff safety controls that are actually enforced.

By End User : 

Hospitals are a major end user group because the big pharmacy departments are dealing with very large amounts of hazardous medicines, and it’s kind of nonstop. Oncology centers push the demand in a more specialized direction, since chemotherapy preparation and administration is happening often, like every day, or week depending on the case, so the workflow stays strict in practice. Specialty clinics and compounding pharmacies also end up needing controlled transfer equipment for medication preparation, especially when hazardous drug procedures are basically routine operations there

Research institutes and pharmaceutical companies add even more pressure too, through lab testing, drug development, and manufacturing steps, all of which can involve handling sensitive materials in a careful manner. Ambulatory surgical centers may be smaller, but they’re still a relevant customer base where medication handling has to stay managed and careful. Home healthcare is another growing application area, because treatment keeps moving out of the usual hospital environment, and the equipment still has to cooperate with that shift When it comes time to buy, the decision will more and more hinge on safety performance, staff usability, how well the product works with existing systems, and the full total operating cost.

By Distribution Channel : 

Direct sales still feel important for big healthcare groups, mostly because they need product demonstrations and on the spot technical support, plus training, and sometimes purchasing that happens through contracts. For hospitals, procurement teams really shape what gets picked, they do it by running standardized purchasing procedures, doing safety evaluations, checking compatibility, and weighing the costs, all in that same cycle. Medical device distributors and those specialty suppliers help widen the market reach too, covering regional facilities as well as smaller clinical customers who may buy less.

Meanwhile online medical stores add another path for getting standardized products and the replacement accessories. Government supply channels also back institutional procurement, especially when public healthcare facilities stick to centralized purchasing frameworks. Wholesalers, for their part, keep products actually available across multiple locations, rather than leaving gaps. Going forward, distribution strategies will probably lean harder on dependable inventory, hands on technical assistance, faster fulfillment, and long term customer relationships, since purchasing teams want fewer supply interruptions, and they want consistency more than anything.

What are the Key Use Cases Driving the United States Closed System Transfer Devices Market?

Hazardous drug handling is still kinda the main use case, especially in hospital pharmacies and oncology centers. For chemotherapy, preparation causes these repeated purchasing cycles because the hospitals have to manage exposure during the drug transfer, the actual prep work, and then administration. So pharmacy procurement teams tend to pick equipment that backs up the safety procedures they already have, and also keeps handling practices consistent.

On another front, biopharmaceutical manufacturing is getting more traction too, since pharmaceutical companies are using controlled processes for advanced therapies. Research institutes likewise use protected transfer equipment in clinical research and lab operations where hazardous compounds need controlled management. Then there are specialty clinics, which are becoming a bigger buyer group as outpatient oncology services keep expanding.

Cell and gene therapy manufacturing is an emerging use case that looks strong for the long run. Home healthcare too may be an early opening, because some selected treatments are drifting toward outpatient and home based delivery. Regulatory expectations around hazardous drug protection will likely help adoption, as these applications move into broader commercial use.

Which Regions are Driving the United States Closed System Transfer Devices Market Growth?

The Northeast keeps the strongest regional position, but publicly available sources do not really give a verified, state-level percentage for the U.S. market. Still, dense hospital networks, large oncology centers, and strict hazardous drug handling practices, help adoption stay higher across the area. There’s also a kind of concentrated healthcare ecosystem that makes procurement work through big hospital systems, specialty pharmacies, distributors, and national suppliers. Leadership will probably keep getting support through 2033 because the established oncology infrastructure and compliance-heavy purchasing keep CSTD requirements coming back, in a recurring way.

The Midwest looks more like a manufacturing and regional health system centered revenue foundation, with large hospital networks backing steady procurement rather than extremely concentrated coastal pull. Pharmacy routines remain consistent, oncology services are already in place, and ongoing institutional purchasing leads to predictable replacement and replenishment needs. Regional hospitals also tend to benefit from standardized procurement programs that can allow longer supplier relationships, plus repeat orders. So this setup makes the Midwest a dependable contributor, even when specific healthcare projects wobble around a bit.

The South is showing the quickest regional opportunity , as expansion in healthcare capacity, oncology infrastructure, plus hospital spending keeps widening the pool of possible customers. With population growth and the ongoing development of big healthcare systems, more places are being added that need hazardous-drug preparation and administration controls. New entrants can aim for regional hospital groups, specialty clinics, and pharmacy networks instead of just depending on the biggest academic centers. Then from 2026 through 2033, the opportunity seems to lean toward suppliers that can deliver scalable training, dependable distribution, strong product compatibility, and procurement assistance.

Who are the Key Players in the United States Closed System Transfer Devices Market and How Do They Compete?

Competition still seems pretty consolidated-ish, with BD, EQUASHIELD, ICU Medical, Corvida Medical, and a bunch of other suppliers sort of going at it mostly by leaning on containment technology, workflow efficiency, product breadth, and the whole service support angle instead of, just price by itself. BD is trying to hold on to its share with the PhaSeal platform, while EQUASHIELD leans into pressure-equalization technology and also plugs into pharmacy automation, kind of a one-two. ICU Medical shows up with its wide IV portfolio and those needle-free connection technologies, which basically lets hospital buyers assemble a broader equipment ecosystem.

BD, in particular, bumped up its tech footing via PhaSeal Optima. That one is designed to align with the NIOSH CSTD definition, and it’s meant to target vapor, aerosol, spill, and contamination control. EQUASHIELD meanwhile is pursuing a more focused, technology specialization path through automated compounding integration and CellSHIELD, launched in September 2025 for cell and gene therapy manufacturing. The CellSHIELD rollout also expands EQUASHIELD reach to biopharmaceutical customers beyond the usual oncology workflows, so it’s not just the conventional lane anymore.

ICU Medical is pushing outward in a more expanded IV-system direction, so kind of broader reach, and there is this 2025 joint venture with Otsuka Pharmaceutical Factory that essentially set up a North American manufacturing network with an estimated annual capacity around 1.4 billion units. Meanwhile Corvida Medical is going the other route, competing with very specialized CSTD products like Halo, and they tend to zero in on hazardous-drug containment for hospital pharmacy environments, rather than the general stuff. Going forward, competitive advantage will probably depend less on one single feature and more on how well they can blend validated containment performance with manufacturing resilience, automation friendliness, training support, and those broader relationships across the healthcare system.

Company List

• BD (Becton Dickinson)
• ICU Medical
• Equashield LLC
• Simplivia Healthcare
• Yukon Medical
• Baxter International
• Braun Melsungen AG
• Fresenius Kabi
• Smiths Medical
• CODAN Medizinische Geräte
• West Pharmaceutical Services
• Corvida Medical
• JMS Co. Ltd.
• MedXL Inc.
• Cardinal Health 

Recent Development News

In September 2025, EQUASHIELD launched CellSHIELD, a closed, sterile, disposable transfer system for cell and gene therapy manufacturing. The launch extends CSTD technology beyond conventional hazardous-drug workflows and opens an additional market opportunity among biopharmaceutical companies and contract development and manufacturing organizations. 

Source: https://www.prnewswire.com/

In December 2025, B. Braun launched its Supply Assurance Program, guaranteeing 45 days of inventory at selected distributor warehouses and including the company’s CSTD portfolio. The initiative strengthens supply continuity for U.S. healthcare providers and reduces disruption risk for hospitals purchasing closed-system transfer devices.

Source: https://www.bbraunusa.com/

What Strategic Insights Define the Future of the United States Closed System Transfer Devices Market?

In the next five to seven years, the market is likely to drift, away from plain exposure control and more toward those integrated medication safety systems. Procurement teams will more and more choose devices that hook into automated compounding, digital workflow documentation, and a wider set of pharmacy tools. So interoperability starts mattering as a stronger edge than just standalone containment capability , or whatever. There is also this kind of less visible hazard: supplier concentration . When hospitals rely on only a small set of specialized manufacturers, they can get hit with shortages, extended lead times , and steeper replacement bills if anything interrupts production.

At the same time, a fresh opening is showing up in cell and gene therapy manufacturing. In that space, closed transfer solutions can help with controlled movement of high-value biological materials, and it can also lower contamination concerns. Because of that, market players should focus on platform compatibility , not only isolated device sales. Established firms can build more steady recurring revenue through bundled equipment plus service agreements. New entrants, though, should aim at specialized therapy manufacturing and healthcare networks region by region, offering solutions that are validated and frankly, easy to integrate.

United States Closed System Transfer Devices Market Report Segmentation

By Product Type

• Vial Access Devices
• Syringe Safety Devices
• Bag/Line Access Devices
• Closed System Transfer Components
• Transfer Sets
• Injection Adapters
• Needle-Free Systems
• Membrane-to-Membrane Systems
• Accessories

By Technology

• Membrane-to-Membrane Technology
• Needleless Technology
• Air Filtration Technology
• Mechanical Barrier Systems
• Pressure Equalization Systems
• Hybrid Systems
• Closed Connector Technology
• Sealed Transfer Systems

By Application

• Hazardous Drug Handling
• Chemotherapy Drug Transfer
• Pharmacy Compounding
• Drug Administration
• Biopharmaceutical Manufacturing
• Clinical Research
• Laboratory Use
• Hospital Pharmacy

By End User

• Hospitals
• Oncology Centers
• Specialty Clinics
• Compounding Pharmacies
• Research Institutes
• Pharmaceutical Companies
• Ambulatory Surgical Centers
• Home Healthcare

By Distribution Channel

• Direct Sales
• Hospital Procurement
• Medical Device Distributors
• Specialty Suppliers
• Online Medical Stores
• Government Supply
• Wholesalers